Ones To Watch News
Refine Search
Biotechnology
Genetic medicines company Scribe Therapeutics has announced an expanded collaboration with French pharma major Sanofi. 18 July 2023
Biotechnology
Privately held, venture-funded biotech Revolo Biotherapeutics today announced additional data from its proof of concept, two-week, three-dose, Phase IIa clinical trial evaluating the efficacy, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in adults with active eosinophilic esophagitis (EoE). 18 July 2023
Biotechnology
UK-based CAR-T therapies specialist Leucid Bio today announced the appointment of Filippo Petti as its chief executive (CEO), with immediate effect. 18 July 2023
Pharmaceutical
Mirum Pharmaceuticals, a US biopharma dedicated to transforming the treatment of rare liver diseases, is to buy Travere Therapeutics’ bile acid product portfolio. 17 July 2023
Biotechnology
Belgo-Dutch autoimmune diseases specialist argenx has announced positive top-line results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in chronic inflammatory demyelinating polyneuropathy (CIDP). 17 July 2023
Pharmaceutical
BridgeBio Pharma saw its shares rocket 66% to $30.30 pre-market as it released long anticipated trial results for its acoramidis. 17 July 2023
Pharmaceutical
Elmar Schnee has been named the new executive chairman of EnteroBiotix, a company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics. 17 July 2023
Biotechnology
Shares in US biopharma Acumen Pharmaceuticals were up by around 50% in pre-market trading on Monday. 17 July 2023
Pharmaceutical
On Sunday, Singapore-headquartered TauRx Pharmaceuticals presented new data from the Phase III LUCIDITY trial that measured the impact of the company’s drug candidate, hydromethylthionine mesylate (HMTM), on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration 17 July 2023
Biotechnology
After markets closed on Thursday, US clinical-stage biotech Theseus Pharmaceuticals announced that it is discontinuing enrollment in the ongoing Phase I/II study and terminating development of its lead candidate THE-630 in patients with gastrointestinal stromal tumors (GIST). 14 July 2023
Biotechnology
US cell and gene therapy biotech Frequency Therapeutics saw its share leap more than 62% to $0.65 pre-market Friday, after announcing an agreement with RNA editing company Korro Bio to merge in an all-stock transaction. 14 July 2023
Pharmaceutical
Shares of First Wave BioPharma closed down more than 32% at $0.90 on Thursday, after the company said a Phase II study of an enhanced formulation of its adrulipase drug candidate seems likely to have missed its primary efficacy endpoint. 14 July 2023
Biotechnology
Privately-held US biotech KSQ Therapeutics, a developer cancer therapies using its proprietary CRISPRomics discovery platform, has entered into a worldwide license agreement with Swiss pharma giant Roche. 14 July 2023
Biotechnology
A stronger focus on oncology, and in particular well known targets such as the HER2 and HER3 proteins, marks a change in strategy for Hillstream BioPharma. 13 July 2023
Biotechnology
The USA’s health technology assessor the Institute for Clinical and Economic Review (ICER) today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of two sickle cell disease gene therapies. 13 July 2023
Biotechnology
Recursion, a tech-bio firm seeking to decode biology to industrialize drug discovery, has announced a $50 million investment by US tech firm NVIDIA (Nasdaq: NVDA), which was executed as a private investment in public equity (PIPE). 13 July 2023
Biotechnology
France’s Abionyx Pharma today announced the appointment of Laurent Guerci as chief digital and innovation officer. 13 July 2023
Biotechnology
French ophthalmology biotech company Nicox has provided details of a US market survey evaluating the commercial potential of its investigational drug NCX 470, a nitric oxide (NO)-donating bimatoprost aimed at treating angle ocular or ocular hypertension. 13 July 2023
Biotechnology
As interest in advanced therapies continues to surge, a new ophthalmic specialist focused on cell-based medicines has been launched with $70 million in series A financing. 13 July 2023
Biotechnology
ADC Therapeutics has announced a pause in patient enrollment in the Phase II LOTIS-9 trial of Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously-untreated diffuse large B-cell lymphoma. 12 July 2023
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze